Intellia Therapeutics, Inc. NTLA Stock Forecast
AI-powered price prediction and analysis for Intellia Therapeutics, Inc. · Alpha · vs marketSwitch to Total
See NTLA's Exact Price Target · Create a free account and follow this stock to unlock its full AI forecast — 3 stocks free.
Price Chart
Key Statistics
About Intellia Therapeutics, Inc.
Intellia Therapeutics, Inc. (NTLA) operates within the Life Sciences sector, specifically in the In Vitro & In Vivo Diagnostic Substances industry.
Latest News
Where NTLA sits on the market map
In Vitro & In Vivo Diagnostic Substances Peers
Companies sharing the same SEC industry code, one row per issuer, largest first - a classification match, not a curated list of competitors.
| Company | AI Signal | Market Cap | P/E |
|---|---|---|---|
| NTLA Intellia Therapeutics, Inc. | ▲ | $1.67B | – |
| IDXX Idexx Laboratories Inc /De | ▼ | $40.99B | 36.0x |
| LNTH Lantheus Holdings, Inc. | ▼ | $6.53B | 23.7x |
| NEOG Neogen Corp | ▲ | $2.56B | – |
| CLDX Celldex Therapeutics, Inc. | ▲ | $2.22B | – |
| QDEL Quidelortho Corp | ▶ | $967M | – |
| ACHV Achieve Life Sciences, Inc. | ▶ | $720M | – |
| TKNO Alpha Teknova, Inc. | ▲ | $441M | – |
| MYGN Myriad Genetics Inc | ▲ | $390M | – |
| ICCC Immucell Corp /De/ | ▲ | $98M | – |
| IMDX Insight Molecular Diagnostics Inc. | ▲ | $98M | – |
| AWHL Aspira Women's Health Inc. | ▲ | $12M | – |
| BMRA Biomerica Inc | ▲ | $8M | – |
| CDIO Cardio Diagnostics Holdings, Inc. | ▶ | $5M | – |
| VNRX Volitionrx Ltd | ▼ | $3M | – |
| QCLS Q/C Technologies, Inc. | ▼ | N/A | – |
| TRIB Trinity Biotech Plc | ▼ | N/A | – |
FAQ
Is Intellia Therapeutics, Inc. a good stock to buy?
Our AI analyzes Intellia Therapeutics, Inc. daily. Check the signal above for the latest recommendation. Always do your own research before investing.
How accurate are Intellia Therapeutics, Inc. predictions?
A per-ticker accuracy statistic for NTLA is published only once its sample size is known. Across our coverage, the out-of-sample test on 4537 stocks from 2025-01-06 to 2026-06-09 produced a positive net return in 73.7% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
How often are forecasts updated?
Intellia Therapeutics, Inc. forecasts are refreshed on trading days as the daily model run completes. The forecast on this page was produced on Oct. 14, 2026.
Ready to invest smarter? · Join thousands of investors using AI-powered stock predictions
Sign Up FreeLooking for a deeper analysis of Intellia Therapeutics, Inc.? View full institutional-grade analysis on Intratio →
AI predictions are based on historical patterns and should not be the sole basis for investment decisions. Past performance does not guarantee future results. Always do your own research.